8-K
filed January 8, 2024, 6:59 PM ET
ticker ALUR
CIK 0001964979
earnings
confidence high
sentiment neutral
materiality 0.80
Allurion prelim 2023 rev $53-54M, cuts 30% staff, 2024 outlook $60-65M
ALLURION TECHNOLOGIES, INC.
2023-FY EPS reported
-$2.31
revenue$53,467,000
- Full-year 2023 revenue expected $53-54M; gross margin 77-78%; procedural volume up 30% YoY.
- Q4 2023 revenue expected $8.1-8.3M; European procedural volume grew 44% in Q4 vs prior year.
- Cash balance $38M as of Dec 31, 2023; Q4 cash burn $22M; term loan reduced by $20M to $40M.
- Reduced headcount ~30% since Dec 2023 to cut quarterly cash burn to $7-8M in 2024.
- 2024 outlook: revenue $60-65M, procedural volume growth ~20%, gross margins 77-79%; FDA pivotal trial readout (AUDACITY) expected by year-end.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ALLURION TECHNOLOGIES, INC. reported the fiscal year ended December 31, 2023 results: revenue $53 - $54 million.
- Period
- the fiscal year ended December 31, 2023
- Revenue
- $53 - $54 million
- Result
- preliminary results
Exact text from the filing
2023 full year revenue is expected to be in the range of $53 - $54 million
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ALLURION TECHNOLOGIES, INC. reported the quarter ended December 31, 2023 results: revenue $8.1 - $8.3 million.
- Period
- the quarter ended December 31, 2023
- Revenue
- $8.1 - $8.3 million
- Result
- preliminary results
Exact text from the filing
Fourth quarter revenue is expected to be in the range of $8.1 - $8.3 million
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ALLURION TECHNOLOGIES, INC. reported fiscal year 2024 results: revenue $60 - $65 million. Guidance initiated.
- Period
- fiscal year 2024
- Revenue
- $60 - $65 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
24 Outlook • Anticipated procedural volume growth of approximately 20%, despite a reduction in overall marketing spend, reflecting increased penetration in key direct markets and reallocation of marketing spend to more efficient channels • Revenue guidance of $60 - $65 million , reflecting growth of approximately 13% - 23% year over year • Expected gross margins of 77-79%, reflecting durable pricing of our gastric balloon as well as initial commercialization efforts of the digital platform • Targeted cash burn reduced to approximately $7 - $8 million per quarter Key 2024 Growth Catalysts • Accelerated procedure volume growth across direct markets where Allurion has fully established direct sales and support models • Release of new clinical data, including the AUDACITY FDA pivotal trial read-out expected by end of year, and additional data validating Allurion’s best-in-class weight loss a
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.